The latest clinical breakthroughs, practice management updates, and national advocacy alerts directly from the American Academy of Ophthalmology.
Sustained-released dexamethasone shows promise in dry eye
Ocular Therapeutix announced promising topline results from a phase 2 clinical trial of sustained-released dexamethasone for inflammatory dry eye disease.
We extend our deepest gratitude to our Platinum, Gold, and Silver partners. Your generous support fuels our mission to advance medical education, advocate for patient safety, and foster breakthrough innovations across West Virginia.